Recursion Pharmaceuticals
RXRX
192 hedge funds and large institutions have $1.16B invested in Recursion Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 74 increasing their positions, 38 reducing their positions, and 20 closing their positions.
180% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 20
95% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 38
22% more capital invested
Capital invested by funds: $953M → $1.16B (+$212M)
22% more funds holding
Funds holding: 158 → 192 (+34)
5.54% more ownership
Funds ownership: 69.08% → 74.62% (+5.5%)
3% less call options, than puts
Call options by funds: $5.88M | Put options by funds: $6.09M
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$61.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$60.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.4M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$26.8M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$26.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$22.7M |
| 2 |
MMX
MV Management XI
Menlo Park,
California
|
-$11.8M |
| 3 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
-$8.77M |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$6.59M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
HSBC Holdings
London,
United Kingdom
| – | -$148K | -19,495 | Closed |
|
|
FRM
202
Fox Run Management
Greenwich,
Connecticut
| – | -$141K | -18,917 | Closed |
|
|
VIA
203
Vident Investment Advisory
Alpharetta,
Georgia
| – | -$133K | -17,849 | Closed |
|
|
CF
204
Centaurus Financial
Anaheim,
California
| – | -$99K | -13,242 | Closed |
|
|
HF
205
HRT Financial
New York
| – | -$91K | -12,314 | Closed |
|
|
AWM
206
Accel Wealth Management
Waverly,
Iowa
| – | -$77.2K | -10,330 | Closed |
|
|
DU
207
Delphia (USA)
Toronto,
Ontario, Canada
| – | -$76.3K | -10,212 | Closed |
|
|
ODG
208
O'Dell Group
Cincinnati,
Ohio
| – | -$8.78K | -1,175 | Closed |
|
|
CIA
209
Cape Investment Advisory
Mcdonough,
Georgia
| – | -$1.87K | -250 | Closed |
|
|
CG
210
Cutler Group
San Francisco,
California
| – | -$2K | -200 | -67% |
|
211
US Bancorp
Minneapolis,
Minnesota
| – | -$859 | -115 | Closed |
|
|
C
212
Covestor
London,
United Kingdom
| – | -$20 | -2 | -11% |
|
RXRX Hedge Fund Activity: Q3 2023 in Review
192 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2023, worth a combined $1.16B — up 22% from $953M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new RXRX positions and 20 closed out — a net gain of 36 holders — while 74 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $61.2M. The largest seller was Laurion Capital Management, cutting an estimated $22.7M.
- 192 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2023, up from 158 in Q2 2023.
- Funds reported $1.16B of Recursion Pharmaceuticals stock for Q3 2023, up 22% quarter-over-quarter.
- 56 funds opened new Recursion Pharmaceuticals positions in Q3 2023 and 20 closed out, a net change of +36 holders.
- The largest Recursion Pharmaceuticals buyer in Q3 2023 was Fidelity Investments, an estimated $61.2M added.
- The largest Recursion Pharmaceuticals seller in Q3 2023 was Laurion Capital Management, an estimated $22.7M sold.
Based on aggregated 13F filings for Q3 2023.